Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CAH · NYSE · United States · Wholesale-Drugs, Proprietaries & Druggists' Sundries
In shortCARDINAL HEALTH INC is profitable.
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 1.0% | 20/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 0.7% | 23/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | – | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 34.1% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 0.88× | 7/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 1.13× | 82/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 7.51× | 57/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -0.22 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 1.8% | 27/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 2.64× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 4 of 5 | 80/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 6.5% | 87/100 |
| Operating margin volatility | 0.6% | 100/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 7.4% | 58/100 |
|---|---|---|
| EPS growth, 3-year average | 79.0% | 100/100 |
Weight in the score: 10%
Fiscal year 2026 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 181,326 | 204,979 | 226,827 | 222,578 | 254,248 |
| Cost of revenue | 174,842 | 198,105 | 219,413 | 214,410 | 244,474 |
| Gross profit | 6,484 | 6,874 | 7,414 | 8,168 | 9,774 |
| Selling, general & admin | 4,512 | 4,800 | 5,000 | 5,382 | 6,132 |
| Operating income | (607) | 752 | 1,243 | 2,275 | 2,613 |
| Interest expense | 147 | 84 | 51 | 215 | 348 |
| Pre-tax income | (784) | 663 | 1,201 | 2,101 | 2,174 |
| Income tax | 153 | 332 | 348 | 532 | 469 |
| Net income | (938) | 330 | 852 | 1,561 | 1,714 |
| Diluted EPS | −$3.37 | $1.26 | $3.45 | $6.45 | $7.23 |
| Diluted shares (millions) | 279 | 262 | 247 | 242 | 237 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
−0.22 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
8/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 11, 2026